End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.49 CNY | +1.92% | -0.79% | -8.43% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.43% | 1.42B | - | ||
-6.06% | 12.09B | B+ | ||
-3.26% | 8.21B | B- | ||
+5.17% | 5.74B | B | ||
+31.20% | 5.64B | C | ||
-9.05% | 4.16B | C | ||
-56.99% | 2.88B | D+ | ||
+11.87% | 2.69B | - | - | |
-7.96% | 2.33B | B- | ||
+25.34% | 2.17B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300406 Stock
- Ratings Beijing Strong Biotechnologies,Inc.